Loading...
Loading...
HARP| Name | Value |
|---|---|
| Revenues | 4.4M |
| Cost of Revenue | 0.2M |
| Gross Profit | 4.2M |
| Operating Expense | 16.6M |
| Operating I/L | -12.1M |
| Other Income/Expense | 10.3M |
| Interest Income | 0.5M |
| Pretax | -1.8M |
| Income Tax Expense | -0.2M |
| Net Income/Loss | -1.8M |
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company specializing in developing T cell engagers to harness the immune system's power for treating cancer and other diseases. Their Tri-specific T cell activating construct (TriTAC) product candidates, including HPN328, HPN217, and HPN536, are in various stages of clinical trials for treating small cell lung cancer, multiple myeloma, ovarian and pancreatic cancer, and other tumors. Additionally, they have a preclinical stage product, HPN601, targeting multiple solid tumor indications. The company generates revenue through the development and commercialization of these proprietary TriTAC platform technology products, including a collaboration and license agreement with AbbVie Biotechnology Ltd.
